CClinicalTrials.gg
CompletedNCT03798847JIIXRUpdated Jul 14, 2023

Safety and Performance of Journey II XR Total Knee System

An observational study in Journey II XR Total Knee System, sponsored by Smith & Nephew, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-14.

Sponsored by Smith & Nephew, Inc. · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
683
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to estimate the safety and performance of Journey II XR TKS based on retrospective data.

02

Conditions studied

  • Journey II XR Total Knee System

Keywords

  • Journey II XR Total Knee System
03

In context

Lead sponsor

Smith & Nephew, Inc. is the lead sponsor of 132 studies on the registry; 10 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subject received primary uni- or bi-lateral total knee arthroplasty with the Journey II XR TKS for approved indication

Inclusion criteria

  • Subject received primary uni- or bi-lateral total knee arthroplasty with the Journey II XR TKS for approved indication;
  • The TKA occurred at least 12 weeks prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
683 participants (actual)
Patient registry
No

Interventions

  • DeviceJourney II XR TKA

    Journey II XR Total Knee System

06

What researchers measure

Primary outcomes

  1. Revision of one or more study device components

    Measure of the number of revision cases

    Time frame: 12 weeks follow up

Secondary outcomes

  1. Adverse Events

    All collected and reported AEs

    Time frame: 12 weeks follow up

  2. Health care utilization: Hospitalization

    Length of hospital stay for primary (index) surgery

    Time frame: implantation through study completion, approximately 3 years

  3. Health care utilization: Hospitalization

    Hospitalizations (admission for inpatient care) occurring after the hospitalization for the index surgery (number and length of stay)

    Time frame: Implantation through study completion, approximately 3 years

  4. Health care utilization: Rehabilitation

    number of sessions and duration of rehabilitation in weeks

    Time frame: Implantation through study completion, approximately 3 years

  5. Health care utilization: Outpatient visits

    Number and type of outpatient visits

    Time frame: Implantation through study completion, approximately 3 years

  6. Health Care Utilization: Re-operations

    Number of re-operations and revisions

    Time frame: Implantation through study completion, approximately 3 years

  7. Quality of Life: EQ-5D-3L

    EuroQol Five Dimensions Questionnaire

    Time frame: Implantation through study completion, approximately 3 years

  8. Quality of Life: KSS

    2011 Knee Society Score

    Time frame: Implantation through study completion, approximately 3 years

  9. Return to Work

    Changes in employment status will be recorded with the date on which the change occurred and the change status.

    Time frame: Implantation through study completion, approximately 3 years

  10. Technical Difficulties Encountered During Device Implantation

    Number of technical difficulties encountered with the device

    Time frame: Implantation through study completion, approximately 3 years

07

Study locations

12 sites
  • Orthopedic Institute of the West
    Phoenix, Arizona 85054, United States
  • Rush Copley Orthopaedics
    Aurora, Illinois 60504, United States
  • Jerry Orthopaedic Institute
    Port Huron, Michigan 48060, United States
  • Reno Orthopedic Clinic
    Reno, Nevada 89503, United States
  • Orthopaedic Center of New Jersey
    Somerset, New Jersey 08873, United States
  • Hospital for Joint Diseases Orthopaedics Institute
    New York, New York 10003, United States
  • Regenerative Orthopedic Center (ROC)
    Oregon City, Oregon 97045, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • San Antonio Orthopaedic Specialists
    San Antonio, Texas 78258, United States
  • Anderson Orthopaedic Clinic
    Alexandria, Virginia 22306, United States
  • Scott Orthopedic Center
    Huntington, West Virginia 25702, United States
  • Aurora Medical Center
    Kenosha, Wisconsin 53142, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03798847
Lead sponsor
Smith & Nephew, Inc.
Responsible party
Sponsor
First posted
Jan 10, 2019
Start date
Nov 1, 2018
Primary completion
Sep 10, 2020
Completion
Sep 10, 2020
Last update
Jul 14, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion